Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Bror Morein

Novavax, Inc.

Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research, development, and commercialization of novel vaccines and biologic therapeutic candidates for infectious diseases, and cancer and autoimmune diseases. It is developing SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine candidate that is in Phase II/III clinical trial; SCB-313, a trimeric fusion protein for the treatment of malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis to address the global unmet medical need of intracavitary malignancies; SCB-808 that is in pivotal Phase III clinical trial for the treatment of rheumatic diseases; SCB-420, an aflibercept biosimilar that is in pre-clinical development for ophthalmologic diseases, such as wet age-related macular degeneration; and SCB-219, a novel TPOR agonist that is in pre-clinical development for the treatment of chemotherapy-induced thrombocytopenia and immune thrombocytopenic purpura. The company has a collaboration and supply arrangement with Dynavax to supply its CpG 1018 adjuvant for pre-clinical studies. Clover Biopharmaceuticals, Ltd. was founded in 2007 and is headquartered in Shanghai, China.

Clover Biopharmaceuticals, Ltd.

Fairmount is a Philadelphia-based investment firm dedicated to investing in promising new therapies pursued by biotechnology and life science companies.

Fairmount Funds

Sierra Oncology is a focused biopharma company that aims to impact global health by addressing high burden diseases through scientific research and innovation, particularly in infectious diseases, HIV, immunology/respiratory, and oncology.

Sierra Oncology

Events at Novavax

We’re making a difference in the health of people around the world by producing next generation vaccines that are accessible to more people. We stand strong against infectious diseases and viral threats—our science grounds us, our technology pushes us forward, our commitment inspires us to achieve our hopes. We do this work for the greater health of people everywhere. It’s more than our job. It’s our passion.

Our Novavax Social Community Guidelines: https://www.novavax.com/social-media-community-guidelines

Bill & Melinda Gates Foundation

Coalition for Epidemic Preparedness Innovations

Government of United States of America

Innovations Kapital

SK Bioscience

RA Capital Management

Novavax

Join Lucie Kutikova, PhD, Senior Director, Real World Evidence, Head of Europe & Middle East, Jonas Lundkvist, Senior Director, Real World Evidence, Europe region, and Chengbin Wang, Senior Director, Safety Epidemiology and Benefit Risk, as they present at #ISPOREurope 2023. 
 
Learn more: https://lnkd.in/dviJMvMS

Join Matt Rousculp, Vice President, Real World Evidence, as he presents at #ISPOREurope 2023 on November 13 from 10:30-13:30 UTC. 
 
Learn more: https://lnkd.in/dviJMvMS  
 
#ISPOREurope #NovavaxEurope #Announcement

Novavax is attending ISPOR—The Professional Society for Health Economics and Outcomes Research Europe 2023 on November 12-15 in Copenhagen, Denmark! We look forward to hearing from experts on the role of health economics and outcomes research (HEOR) and how it shapes policy. 
 
Learn more: https://lnkd.in/dviJMvMS  
 
#ISPOREurope #NovavaxEurope #Announcement

Happy #Diwali from all of us at Novavax!✨ We hope this festival of lights fills your life with joy, love, and prosperity.

On this #Veteran’sDay, Novavax honors our nation’s Veteran’s, and the outstanding support Blue Star Families provides to them, every day of the year! #grateful

Novavax is pleased to announce new publications in Scientific Reports and Frontiers in Drug Delivery. View papers here: https://lnkd.in/gUqYnxmx

Nathalie S., Threat Intel Analyst, Information Security, shares the preparation her military service provided that she now utilizes in her role at Novavax.

Novavax is attending the 39th Pulmonology Congress in Algarve, Portugal on November 9-11! We look forward to learning alongside leaders in pulmonology.  
 
Learn more about Novavax Portugal: https://novavax.pt/ 
 
#NovavaxEurope #NovavaxPortugal #Announcement

Don't miss out on the poster presentation from Matt Rousculp, Vice President, Real World Evidence, at the Asian Vaccine Conference!  
 
Learn more: https://asianvaccine.com/

This week, Anthony Q. Singleton, Director of IT End User Services, shares the parallels of his service in the armed forces, and current position at Novavax amid an ongoing worldwide health crisis.

Metric
Company Name	Novavax, Inc.	Clover Biopharmaceuticals, Ltd.	Fairmount Funds	Sierra Oncology
Symbol	NVAX	2.20K
MSH ID	COM:NOVAVAX	COM:CLOVERBIOPHARMA	COM:FAIRMOUNTFUNDS	COM:SIERRAONCOLOGY
Market	STOCKS	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare	Financial Services & Finance	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Investment Management	Pharmaceuticals
Country	US	CN	US	GB
Stage		Post-IPO Equity
Employee Count	1.54K	387
Website	novavax.com	cloverbiopharma.com	fairmountfunds.com	sierraoncology.com
LinkedIn	novavax	cloverbiopharmaceuticals	fairmount-funds-management-llc
Founders

Metric
Market Cap	1.68B	53.38M
Enterprise Value
Monthly Web Traffic		3.49K	88
Web Traffic Growth		0.41	-0.70
Valuation
Raised Capital		36.90M

Metric
Revenue	983.71M	5.40M
Revenue (LTM)
Revenue (NTM)
Gross Profit	704.24M	-230.14M
EBITDA	-373.80M	-354.93M
Operating Income	-415.03M	-358.92M
Net Income	-545.06M	-19.06M
EPS	-5.41	-0.02
Diluted EPS	-5.41	-0.02
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.60	-15.46
Operating Profit Margin	-0.35	-34.22
EBITDA Margin	-0.38	-65.74
Net Profit Margin	-0.36	-3.53
Return on Equity	0.72	2.08
Return on Assets	-0.16	-0.07
Return on Capital Employed	-0.43	14.86

COM:NOVAVAX

Novavax, Inc.

Last Close

8.04

22/11 21:00

Market Cap

1.68B

Beta: -

Volume Today

4.79M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-0.70	-0.17
P/B Ratio	-0.56	-0.64
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	3.54	1.95K
EV Multiple	-1.84	-0.25

Metric
Days Sales Outstanding	55.36
Days Payables Outstanding	100.39
Days Inventory Outstanding	45.07	534.63
Operating Cycle	177.58	1.07K
Cash Conversion Cycle	34.23	1.03K
Asset Turnover	0.61	0.02

Metric
Operating Cash Flow	-717.56M
Free Cash Flow	-776.36M
Cash Flow to Debt	0.08	-1.29
Operating Cash Flow/Sales	0.02	-10.96
Free Cash Flow Yield	-1.65	-3.59

Metric
Cash & Equivalents	578.93M	101.22M
Accounts Receivable	-274.44M
Inventory	41.70M	95.87M
Goodwill	127.45M
Debt to Capitalization	-0.25	0.94
Debt to Assets	0.13	0.08
Current Ratio	0.69	1.55
Quick Ratio	1.03	0.55

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.12
R&D to Revenue	1.02
SG&A to Revenue